mProX™ Human ICOSLG Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ICOSLG, a member of the B7 protein family, has been studied in various contexts. In oral squamous cell carcinoma (OSCC), ICOSLG expression was found in tumor cells, cancer-associated fibroblasts, and tumor infiltrating lymphocytes. High levels of ICOSLG in OSCC were associated with advanced disease stage and poor survival outcomes. Additionally, ICOSLG was correlated with other immune checkpoint molecules and could be used as a marker for patient stratification in precision immunotherapy. In metastatic urothelial carcinoma (mUC) treated with pembrolizumab, the presence of tertiary lymphoid structures (TLS) and a lower neutrophil-lymphocyte ratio (NLR) were associated with improved treatment outcomes. ICOSLG expression was significantly increased in tumors with a lower NLR. In ovarian cancer, TRPM2 expression was correlated with poor prognosis and immune infiltration. TRPM2 may serve as a prognostic factor and a potential immunotherapy target in ovarian cancer. In a pan-cancer cohort, T-cell priming transcriptomic markers (TPMs) were analyzed for their correlation with immunotherapy biomarkers. Diverse expression patterns of TPMs were observed, and individualized selection of patients based on TPM expression profiles may optimize immunotherapy. Finally, genetic impacts on DNA methylation were investigated, revealing that methylation levels at a significant proportion of CpGs are affected by SNPs. Co-localization analyses identified associations between genetic effects on DNA methylation and various human traits, including disease-related genes. These findings contribute to our understanding of regulatory genomic processes and can aid in prioritizing GWAS variants for functional follow-ups.